In 2016, nearly 800 million tablets of ivermectin were distributed to countries for use in elimination programs for human filarial diseases. Despite its widespread use, the mode of action of ivermectin against filarial nematodes is not well understood, and its in vivo potency cannot be replicated in vitro. To better understand how ivermectin affects filarial worms, our lab previously performed a transcriptomics study to identify differently expressed genes (DEG) in Brugia malayi adults and microfilariae after treatment of infected gerbils. Forty-four of these DEG had C. elegans orthologs available as mutant strains through the C. elegans Genetics Center. We have assayed these mutant strains for differential sensitivity to ivermectin by measuring three phenotypes affected by ivermectin: egg production, development, and motility. We have identified several resistant and hypersensitive strains of C. elegans as well as differences between responses to the three assays. Mutations conferring resistance included those in
che-12 (
e1812), a gene involved in chemotaxis, cilium assembly, and hyperosmotic response; and
inx-14 (
ag17), which is predicted to have gap junction hemi-channel activity and is expressed in the muscular, nervous, and reproductive systems. The
che-12 mutants are additionally resistant to ivermectin's effect on pharyngeal pumping, while
inx-14 mutants are not different from control. Overall, twenty-three genes, with eleven strong candidate genes, have been identified as altering ivermectin sensitivity in at least one assay, supporting the validity of the overall approach. These may give insight into how ivermectin acts against filarial parasites as well as potential mechanisms of resistance. These results are currently being used as the basis of an RNAi screen in B. malayi to identify the effect of these candidate genes on ivermectin sensitivity in filarial parasites.